Randomized Trials Sought To Show DES Benefits For Chronic Total Occlusions
This article was originally published in The Gray Sheet
Executive Summary
Despite growing data on the use of drug-eluting stents in the treatment of chronic total occlusions, more trials are needed to establish their benefit, experts say
You may also be interested in...
New Occlusion Devices May Fill Innovation Gap – CTO Summit Panel
Progress in the development of new technologies for treating chronic total occlusions is finally accelerating after years of stagnation, experts reported at the CTO Summit Feb. 5-6 in New York
Cordis goes back to PRISON
Johnson & Johnson/Cordis' drug-eluting Cypher stent is associated with an in-stent restenosis rate of 7% compared to 36% with the Bx Velocity stent in the 200-patient randomized PRISON II trial comparing the stents in patients with chronic total occlusions, according to principal investigator Maarten Suttorp, MD, PhD, St. Antonius Hospital, The Netherlands. Cypher also had a lower target lesion revascularization rate than the bare-metal stent (4% vs. 19%) and a lower MACE rate (4% vs. 20%)...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.